GOVX
GeoVax Labs, Inc.
There isn't enough reported data to score GOVX yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GOVX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
GOVX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GOVX PE Valuation
GOVX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GOVX Forward outlook
There aren't enough analyst estimates for GOVX to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GOVX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$5,728.74 | +$1,741.26 |
| Q2 2024 | -$8,062.74 | -$1,942.74 |
| Q1 2024 | -$8,848.74 | -$3,088.74 |
| Q4 2023 | -$8,716.74 | -$1,246.74 |
| Q3 2023 | -$7,470.00 | +$18,810.00 |
| Q2 2023 | -$6,120.00 | +$21,420.00 |
| Q1 2023 | -$5,760.00 | +$22,050.00 |
| Q4 2022 | -$7,470.00 | +$19,890.00 |
GOVX has the stronger earnings trend. Trailing diluted EPS is down 104% for GOVX versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GOVX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $852.3K | +183% |
| Q1 2022 | $81.5K | -26% |
| Q4 2021 | $165K | -34% |
| Q3 2021 | $30.4K | -93% |
| Q2 2021 | $79.7K | -82% |
| Q1 2021 | $110.4K | -85% |
| Q4 2020 | $251.6K | -6.3% |
GOVX's revenue has slid since its 2024 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -636% | +1048 points |
| Q1 2025 | -330% | N/A |
| Q4 2024 | -965% | N/A |
| Q3 2024 | -210% | N/A |
| Q2 2024 | -1684% | N/A |
| Q1 2022 | -2978% | -1562 points |
| Q4 2021 | -8331% | -7800 points |
| Q3 2021 | -6416% | -6311 points |
GOVX's operating margin was −636% last quarter, up 1048 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GOVX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GOVX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.3M | +$1.9M |
| Q2 2026 | -$3.7M | +$687K |
| Q1 2026 | -$3.5M | +$2.4M |
| Q4 2025 | -$5M | +$2.8M |
| Q3 2025 | -$6.2M | +$3.1M |
| Q1 2025 | -$6M | -$298.8K |
| Q4 2024 | -$7.8M | +$2.5M |
| Q3 2024 | -$9.3M | -$4.2M |
GOVX has burned cash in almost every quarter: −$16M over the past year, against −$24M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GOVX on cash generation, producing positive trailing cash flow while its opponent burns cash.
GOVX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +107% | +203K shares |
| 1 year | +1064% | +360K shares |
| 3 years | +13295% | +391K shares |
| 5 years | +452256% | +393K shares |
GOVX has 393,550 diluted shares, up 1064% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GOVX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GOVX Net Leverage
GOVX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GOVX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 1.4 | Oversold |
GOVX's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GOVX PE vs Healthcare Sector
GOVX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GOVX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.42 | 62% below |
| 20 week MA | $12.9 | 84% below |
| 50 week MA | $43.4 | 95% below |
| 100 week MA | $349.0 | 99% below |
| 200 week MA | $1,907.6 | 100% below |
GOVX is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GOVX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $143,928.0 | $29,520.0 | -79% |
| 2021 | $29,520.0 | $36,180.0 | +23% |
| 2022 | $36,180.0 | $5,106.5 | -86% |
| 2023 | $5,106.5 | $3,249.1 | -36% |
| 2024 | $3,249.1 | $1,476.0 | -55% |
| 2025 | $1,476.0 | $108.7 | -93% |
| 2026 YTD | $108.7 | $2.04 | -98% |
GOVX has finished four years in a row lower, and it's down 98% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over GOVX on returns for 2026, with the stronger performance.